{"id":"telbivudine-standard-of-care","safety":{"commonSideEffects":[{"rate":null,"effect":"Myositis or muscle pain"},{"rate":null,"effect":"Elevated creatine kinase"},{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatitis flare"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telbivudine is a thymidine nucleoside analog that is phosphorylated intracellularly and incorporated into the growing DNA chain of hepatitis B virus, causing chain termination and preventing viral replication. It selectively inhibits HBV reverse transcriptase with high potency and a high genetic barrier to resistance compared to some other nucleoside analogs.","oneSentence":"Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:34.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT01410630","phase":"","title":"FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-09-07","conditions":"Lymphoma, Lymphoma, Non-Hodgkin, Large B Cell Diffuse Lymphoma","enrollment":66},{"nctId":"NCT01529255","phase":"PHASE4","title":"EFFORT Extension Study","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":576},{"nctId":"NCT01788371","phase":"PHASE4","title":"Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus","status":"COMPLETED","sponsor":"Hua Zhang","startDate":"2009-03","conditions":"Hepatitis B Infection, Chronic Infection, Viremia","enrollment":700},{"nctId":"NCT00962533","phase":"PHASE4","title":"EFFicacy Optimization Research of Telbivudine Therapy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2009-08","conditions":"Hepatitis B, Chronic","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Telbivudine (Standard of Care)","genericName":"Telbivudine (Standard of Care)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}